Novel therapeutic approaches for cutaneous T cell lymphomas

Area of Science:

• Dermatology and Oncology
• Immunology
• Molecular Biology

Background:

• Cutaneous T-cell lymphoma (CTCL) is a heterogeneous non-Hodgkin's lymphoma involving malignant T cells in the skin.
• Current treatments for CTCL include skin-directed, radiation, and systemic therapies, but challenges remain due to disease heterogeneity.
• Understanding CTCL pathogenesis is key to developing innovative and personalized treatment strategies.

Purpose of the Study:

• To review the molecular and immunological aspects of CTCL, focusing on Mycosis Fungoides (MF) and Sézary Syndrome (SS).
• To discuss novel systemic treatment approaches for CTCL.
• To evaluate the potential of emerging therapies in managing CTCL.

Main Methods:

• A comprehensive literature search was performed using PubMed and Web of Science.
• Articles published up to November 2020 were included.
• Focus was placed on molecular pathways, immunological aspects, and systemic treatments for CTCL, MF, and SS.

Main Results:

• Novel therapeutic agents such as retinoids, targeted therapies, immune checkpoint inhibitors, JAK/STAT inhibitors, HDAC inhibitors, mTOR inhibitors, and proteasome inhibitors were identified.
• These agents show potential in treating patients with high unmet needs, including refractory early-stage and advanced-stage CTCL.
• Combinations of novel agents with existing treatments may offer improved management strategies.

Conclusions:

• Emerging therapeutic agents hold significant promise for improving outcomes in CTCL patients.
• Personalized treatment schemes incorporating novel agents are crucial for managing refractory and advanced CTCL.
• Further research into combination therapies could enhance the efficacy of CTCL treatment.